Efficacy and Safety of Rituximab Given at Fixed Dose (1000 mg on Days 1 and 15) Compared to the Standard Regimen in Adult's Immune Thrombocytopenia

Henri Mondor University Hospital

Status: Completed

Conditions: Primary Immune Thrombocytopenia

Study type: Observational

Funder types: Other

Identifiers

NCT01727232

Mondor-Rituxcompare

Details and patient eligibility

About

The aim of this large French multicentric retrospective study was to compare the efficacy and safety of two (the standard and the Rheumatoid arthritis) rituximab regimens in adult's immune thrombocytopenia .

Full description

Every adult (age ≥ 18 years) seen in one of the 3 participating centre (dijon, Marseille, Mondor) over a 7-year period (2005-2012) with a definite diagnosis of primary ITP according to the American Society Hematology guidelines who received RTX regardless the regimen could be included.

Enrollment: 107 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Primary ITP
• Age > 18 years

Exclusion criteria

• Secondary ITP
• Age < 18 years

Trial design

107 participants in 2 patient groups

Standard regimen

Description:

Patients received the standard regimen (i.e 4 weekly infusions of 375 mg/m2)of rituximab

Rheumatoid arthritis regimen

Description:

Patients received the RA regimen (i.e two infusions of 1000 mg, 2 weeks apart) of rituximab